-

03:49:26 PM

TGTX Stock News

TGTX - TG Therapeutics Inc

03/29/21 7:42 AM

Nasdaq : TGTX

TG Therapeutics Completes Rolling Submission of Biologics License Application to the U.S. Food and Drug Administration for Ublituximab in Combination with UKONIQ™(umbralisib) as a Treatment for Patients with Chronic Lymphocytic Leukemia

TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the completion of the rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) requesting approval of ublituximab, the Company’s investigational

RHEA-AI

very positive

03/09/21 7:30 AM

Nasdaq : TGTX

clinical trial

TG Therapeutics Announces Publication of Results from the UNITY-NHL Phase 2b Trial Evaluating Umbralisib Monotherapy in Patients with Relapsed or Refractory Indolent non-Hodgkin Lymphoma in the Journal of Clinical Oncology

TG Therapeutics, Inc. (NASDAQ: TGTX) today announced the publication of results from the UNITY-NHL Phase 2b trial evaluating UKONIQ™ (umbralisib), the Company’s inhibitor of PI3k-delta and CK1-epsilon, in patients with relapsed or refractory indolent

RHEA-AI

neutral

03/04/21 4:30 PM

Nasdaq : TGTX

conferencesclinical trial

TG Therapeutics to Present Results from the ULTIMATE I & II Phase 3 Trials Evaluating Ublituximab in Multiple Sclerosis at the Upcoming American Academy of Neurology 73rd Annual Meeting

TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that results of the ULTIMATE I & II Phase 3 trials evaluating ublituximab, the Company’s novel, glycoengineered anti-CD20 monoclonal antibody, in relapsing forms of multiple sclerosis (RMS) have

RHEA-AI

neutral

03/04/21 7:30 AM

Nasdaq : TGTX

conferences

TG Therapeutics to Present at the H.C. Wainwright Global Life Sciences Conference

TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company’s Executive Chairman and Chief Executive Officer, will present at the H.C. Wainwright Global Life Sciences Conference, being held virtually March 9 – 10, 2021. The

RHEA-AI

neutral

03/02/21 7:00 AM

Nasdaq : TGTX

earnings

TG Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2020 Financial Results

TG Therapeutics, Inc. (NASDAQ: TGTX) today announced its financial results for the fourth quarter and year ended December 31, 2020 and recent company developments, along with a

RHEA-AI

very positive

02/26/21 7:30 AM

Nasdaq : TGTX

conferencesearnings

TG Therapeutics to Host Conference Call on Fourth Quarter and Year-End 2020 Financial Results and Business Update

TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held on Tuesday, March 2, 2021 at 8:30 AM ET to discuss results for the fourth quarter and year-end 2020

RHEA-AI

neutral

02/23/21 7:30 AM

Nasdaq : TGTX

clinical trial

TG Therapeutics Announces Publication of Final Results from the Phase 3 GENUINE Trial Evaluating Ublituximab Plus Ibrutinib in Patients with Relapsed/Refractory High-Risk Chronic Lymphocytic Leukemia in The Lancet Haematology

TG Therapeutics, Inc. (NASDAQ: TGTX) today announced the publication of final results from the Phase 3 GENUINE trial evaluating ublituximab, the Company’s investigational glycoengineered anti-CD20 monoclonal antibody, in combination with ibrutinib, in

RHEA-AI

neutral

02/05/21 1:54 PM

Nasdaq : TGTX

TG Therapeutics Announces FDA Accelerated Approval of UKONIQ™ (umbralisib)

UKONIQ is approved for adult patients with relapsed or refractory marginal zone lymphoma after at least one prior anti-CD20 based regimen UKONIQ is approved for adult patients with relapsed or refractory follicular lymphoma after at least three prior lines of systemic therapy UKONIQ is the first

RHEA-AI

very positive

01/15/21 7:00 AM

Nasdaq : TGTX

conferences

TG Therapeutics to Participate in the B. Riley Securities Oncology Investor Conference

TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that Michael S. Weiss, the Company’s Executive Chairman and Chief Executive Officer, will participate in a fireside chat during

RHEA-AI

neutral

01/08/21 7:00 AM

Nasdaq : TGTX

conferences

TG Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference

TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company’s Executive Chairman and Chief Executive Officer, will present at the 39 th Annual J.P. Morgan

RHEA-AI

neutral

Prev 2 3 4 5 6 7 8 9 10 Next

TGTX Data

IndustryPharmaceutical Preparation Manufacturing
Websitewww.tgtherapeutics.com
CeoMichael Weiss
Security nameTG Therapeutics Inc
Issue typecs
SectorManufacturing
Sic code2834
Employees272
Tags
- Health Technology
- Biotechnology
- Manufacturing
- Pharmaceutical Preparation Manufacturing
Address2 Gansevoort St Fl 9
StateNew York
CityNew York
Zip10014-1667
CountryUS
Phone12125544484

About TG Therapeutics Inc

TG Therapeutics is a fully-integrated, commercial stage biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. In addition to an active research pipeline including five investigational medicines across these therapeutic areas, TG has received accelerated approval from the U.S. FDA for UKONIQTM (umbralisib), for the treatment of adult patients with relapsed/refractory marginal zone lymphoma who have received at least one prior anti-CD20-based regimen and relapsed/refractory follicular lymphoma who have received at least three prior lines of systemic therapies. Currently, the Company has two programs in Phase 3 development for the treatment of patients with relapsing forms of multiple sclerosis (RMS) and patients with chronic lymphocytic leukemia (CLL) and several investigational medicines in Phase 1 clinical development.